text in 
English (pdf)
Article in xml format
Curriculum ScienTI
Automatic translation
Cited by SciELO 
Cited by Google 
Similars in
SciELO 
Similars in Google 
Permalink
Introduction
The current standard immunosuppressive regimen for kidney transplant recipients includes induction with basiliximab and maintenance therapy with tacrolimus (TAC), mycophenolate (MPS) and prednisone (PRED).1 Induction therapy with rabbit anti-thymocyte globulin (r-ATG) has been used in an increasing proportion of patients with higher immunological risk and in recipients of kidney recovered from expanded criteria donos.2 This strategy determines lower incidence of acute rejection and superior long term graft survival,3,4 but are associated with higher incidence of cytomegalovirus (CMV)5 and polyomavirus infection.6,7
Due to the increasing use of more effective immunosuppressive regimens, the spectrum of clinical presentations of CMV infection has progressively changed, with significant morbidity and mortality in the absence of preventive strategies. Management of CMV infection is then mandatory but associated with increased direct and indirect costs.8
Currently there are two alternatives for the prevention of CMV infection, universal pharmacological prophylaxis and preemptive treatment. Both strategies have proven efficacy and safety.9 However, the access to pharmacological prophylaxis and to the laboratorial tests for monitoring viral replication, used for preemptive treatment, are limited and not reimbursed by our National Health System.
This study aims to evaluate the incidence of CMV infection and its effect on the major outcomes of kidney transplantation using a contemporary cohort of renal transplant recipients receiving no pharmacological prophylaxis.
Methods
Study design
This single center retrospective study included data extracted from an electronic database and adjudicated by review of medical records. The study was approved by the local Research Ethics Committee (CEP) at UNIFESP under registration C.A.A.E ID: 56366516.5.0000.5505.
Population
For this analysis, all patients who underwent transplantation between 04/30/2014 and 04/30/2015 were initially selected. Patients undergoing simultaneous pancreas-kidney transplants, receiving kidney transplant from HLA identical living donors, and receiving initial immunosuppressive therapy including cyclosporine or everolimus were excluded from the analysis.
Objective
The aim of this study was to determine the incidence and risk factors for CMV infection or disease and its influence on clinical outcomes during the first year after kidney transplantation.
Immunosuppression
Induction therapy with basiliximab was used in pediatric recipients while r-ATG (single 3 mg/kg dose within 24 hours of graft revascularization) was the choice for the majority of adult recipients. All patients received tacrolimus with doses adjusted to maintain blood concentrations between 5-15 ng/mL, combined with MPS (1440 mg/day) or azathioprine (AZA, 2 mg/kg/day). All patients received an initial dose of 0.5 mg/kg/day of prednisone which was progressively reduced to 5 mg/day within 30-45 days after transplantation.
Management of CMV infection/disease
None of the patients received pharmacological prophylaxis for CMV infection. Instead, preemptive treatment was performed in patients deemed as high risk for developing CMV infection: (1) seronegative CMV kidney transplant recipients from seropositive CMV donors (D+/R-); (2) use of r-ATG for induction (3) use of MPS for maintenance therapy; (4) after treatment of acute rejection episodes. The preemptive treatment consisted of monitoring of viral replication every other week from week three until the end of the third month, using the pp65 CMV antigenemia test.
CMV infection was defined as the presence of more than 5 infected cells with pp65 CMV antigen in a total of 200,000 peripheral blood neutrophils in the absence of symptoms or signs of CMV infection. For D+/R- patients the diagnosis of CMV infection was done with any number of infected cells. CMV disease was defined as any number of cells infected with pp65 antigen associated plus characteristic symptoms or signs such as fever, asthenia, myalgia, leukopenia, thrombocytopenia and liver enzymes abnormalities.
All episodes of CMV infection or disease were treated with intravenous ganciclovir with dose adjustments according to renal function, as per package insert. Treatment was monitored weekly and extended for one more week after a negative pp65 CMV antigenemia test, with a minimum of 14 days of ganciclovir. Recurrence of CMV infection or disease was defined as a new episode diagnosed after a previous successful treatment confirmed by a negative pp65 CMV antigenemia test.
Definitions
The episodes of biopsy proven acute rejection (BPAR) were classified according to Banff 2009 criteria. Clinical rejections were defined as graft dysfunction without histological evidence of rejection and treated with methylprednisolone for at least three days. The composite endpoint of efficacy failure included the incidence of the first biopsy proven acute rejection, graft loss, death or loss to follow up. Delayed graft function was defined as the need of dialysis during the first week of transplant. The estimated glomerular filtration rate (eGFR) was calculated using the MDRD-4 equation. Permanent discontinuation of initial immunosuppressive treatment was defined as the withdrawal of one drug or conversion to another alternative drug during the first year of transplantation.
Statistical analysis
Continuous variables were summarized by mean and standard deviation and categorical variables as proportions. The differences between groups were identified using the Student t or Chi square test, respectively. The differences in cumulative survival obtained by the Kaplan-Meier curves were identified by Log Rank test. Logistic regression using one or more variables was used to identify risk factors associated with CMV infection (age and type of donor; age, race, cause of chronic kidney disease, degree of sensitization to HLA antigens [PRA], time on dialysis; pretransplant CMV serology, HLA mismatches, induction therapy, initial immunosuppression with MPS, delayed graft function and acute rejection) and with reduced renal function at 12 months of transplantation (age and type of donor, age, gender, time on dialysis, PRA, HLA mismatches, pretransplant CMV serology, cold ischemia time, delayed graft function, induction therapy, MPS use, acute rejection and recurrent CMV infection or disease).
Only variables with p < 0.05 on univariable analysis were used in the multivariable models. Best surrogate variable was selected among variables showing colinearity to include in multivariable models. All statistical analyzes were performed using SPSS version 18 (SPSS Inc., Chicago, IL, USA) and differences were considered significant for values of p < 0.05.
Results
Population
From April 2014 to April 2015, 938 kidney transplants were performed. One-hundred-thirty-six patients were excluded: 22 simultaneous kidney-pancreas transplants, 37 HLA identical living donor transplants, and 69 patients who received everolimus and 8 who received cyclosporine in the initial immunosuppressive regimen (Figure 1).
The study cohort consisted of 802 recipients; most were adults, males and with a higher prevalence of white and mixed ethnicities. The proportion of patients with chronic kidney disease secondary to diabetes mellitus was 14.9% and the average time on dialysis was 46.1 months. Patients showed low degree of sensitization against HLA antigens. Only 6.2% were CMV D+/R- with additional 2.1% of CMV R- who received kidneys from donors with unknown CMV serostatus. Mean donor age was 44.9 years and 20.9% of the patients received kidneys from living donors. Induction therapy with r-ATG was used in 81.5% and all patients received initial immunosuppression regimens consisted of TAC and PRED, in combination with either MPS (46.3%) or AZA (53.7%).
CMV Infection or disease
The global incidence of CMV infection or disease was 42% (336/802). Patients with CMV infection were older and were on dialysis for a longer period. This group had a higher proportion of patients with diabetes mellitus, with CMV D+ or unknown/R- combinations and higher mean class II PRA. Patients with CMV infection received grafts from older donors and with a higher proportion of expanded criteria donors but with lower HLA mismatches. Finally, of the patients receiving no induction or basiliximab, only 23.6% developed CMV infection (Table 1).
Table 1 Demographic characteristics of study population
| Total N = 802 | With CMV N = 336 | Without CMV N = 466 | p | |
|---|---|---|---|---|
| Recipient age, years (mean ± SD) | 40.2 ± 14.7 | 48.6 ± 13.4 | 41.1 ± 14.8 | 0.000 |
| Recipient gender, N (%) | ||||
| Male | 497 (62.0) | 198 (39.8) | 299 (60.2) | 0.132 |
| Female | 305 (38.0) | 138 (41.2) | 167 (54.8) | |
| Recipient race, N (%) | ||||
| White | 321 (40.0) | 135 (42.1) | 186 (57.9) | 0.011 |
| Black | 105 (13.1) | 36 (34.3) | 69 (65.7) | |
| Mixed | 354 (44.5) | 149 (42.1) | 205 (57.9) | |
| Other | 22 (2.7) | 16 (72.7) | 6 (27.3) | |
| Cause of renal chronic disease, N (%) | ||||
| Glomerulonephritis | 182 (22.7) | 64 (35.2) | 118 (64.8) | 0.000 |
| Hypertension | 86 (10.7) | 47 (54.7) | 39 (45.3) | |
| Diabetes Mellitus | 119 (14.9) | 64 (53.8) | 55 (46.2) | |
| Polycystic kidney disease | 57 (7.1) | 31 (54.4) | 26 (45.6) | |
| Unknown | 284 (35.4) | 104 (36.6) | 180 (66.4) | |
| Other | 74 (9.2) | 26 (35.1) | 48 (64.9) | |
| Time on dialysis, months (mean ± SD) | 46.1 ± 45.7 | 51.6 ± 47.6 | 42.2 ± 44.0 | 0.004 |
| Previous treatment, N (%) | ||||
| Hemodialysis | 684 (85.2) | 284 (41.5) | 400 (58.5) | 0.784 |
| Peritoneal dialysis | 43 (5.4) | 21 (48.8) | 22 (51.2) | |
| Conservative | 36 (4.5) | 14 (38.9) | 22 (61.1) | |
| Hemodialysis/Peritoneal dialysis | 39 (4.9) | 17 (43.6) | 22 (56.4) | |
| Panel of reactive antibodies (mean ± SD) | ||||
| Class I | 9.1 ± 22.0 | 10.9 ± 24.0 | 7.8 ± 20.3 | 0.064 |
| Class II | 4.7 ± 16.5 | 6.0 ± 18.2 | 3.8 ± 15.1 | 0.050 |
| HLA mismatch (mean ± SD) | 2.5 ± 1.3 | 2.3 ± 1.2 | 2.6 ± 1.3 | 0.001 |
| Pre-transplant CMV IgG, N (%) | ||||
| Donor +/Recipient + | 573 (71.5) | 222 (38.7) | 351 (61.3) | 0.001 |
| Donor +/Recipient - | 50 (6.2) | 33 (66) | 17 (34) | |
| Donor -/Recipient + | 34 (4.2) | 13 (38.2) | 21 (61.8) | |
| Donor unk/Recipient + | 126 (15.7) | 55 (43.7) | 71 (56.3) | |
| Donor -/Recipient - | 2 (0.3) | 1 (50) | 1 (50) | |
| Donor(unk/Recipient - | 17 (2.1) | 12 (70.6) | 5 (29.4) | |
| Donor age, years (mean ± SD) | 44.4 ± 15.3 | 47.3 ± 14.8 | 42.3 ± 15.4 | 0.000 |
| Donor, N (%) | ||||
| Living donor | 168 (20.9) | 41 (24.4) | 127 (75.6) | 0.000 |
| Standard criteria deceased donor | 451 (56.3) | 177 (39.2) | 274 (60.8) | |
| Expanded criteria deceased donor | 183 (22.8) | 118 (64.5) | 65 (35.5) | |
| Cold ischemia time (mean ± SD) | 24.5 ± 6.7 | 24.9 ± 6.7 | 24.4 ± 6.8 | 0.417 |
| Induction therapy, N (%) | ||||
| No induction | 97 (12.1) | 26 (26.8) | 71 (73.2) | 0.000 |
| Thymoglobulin | 654 (81.5) | 301 (46) | 353 (54) | |
| Basiliximab | 51 (6.4) | 9 (17.6) | 42 (82.4) | |
| Initial immunosuppression, N (%) | ||||
| TAC+MPS+Pred | 371 (46.3) | 193 (52) | 178 (48) | 0.000 |
| TAC+AZA+Pred | 431 (53.7) | 143 (33.2) | 288 (66.8) | |
SD: standard deviation; CMV: cytomegalovirus; HLA: human leucocyte antigen; (unk): unknown; TAC: tacrolimus; MPS: sodium mycophenolate; AZA: azathioprine; Pred: prednisone.
CMV infection (58.6%) was more frequent than CMV disease (41.4%). Because of the pretransplant serostatus prevalence, the majority of the episodes (66.1%) occurred among CMV D+/R+. Of the 336 first episodes of CMV infection/disease, 47 (14%) were preceded by an episode of acute rejection. Of 65 patients with first treated acute rejection episodes, 19 (29%) occurred after the first episode of CMV infection/disease.
The incidence of recurrence of CMV infection or disease was 36%, ranging between 1 and 5 episodes per patient, and yielding a total of 514 episodes of CMV infection or disease diagnosed in 336 patients. Importantly, 46% of the patients with CMV infection/disease required transient or permanent changes in MPS or AZA dosages (Table 2).
Table 2 Characteristics of CMV infection or disease episodes
| Variable | Total N = 802 | MPS N = 371 | AZA N = 431 |
|---|---|---|---|
| Incidence of first CMV event, N (%) | 336 (42.0) | 193 (52.0)(1) | 143 (33.0) |
| Infection | 197 (58.6) | 121 (62.7) | 76 (53.2) |
| Disease | 139 (41.4) | 72 (37.3) | 67 (46.8) |
| Time to first CMV event, days (mean ± SD) | 47.4 ± 30.1 | 41.1 ± 18.2(1) | 55.8 ± 39.6 |
| Duration of treatment, days (mean ± SD) | 20.1 ± 9.1 | 20.3 ± 9.8 | 19.8 ± 7.8 |
| Incidence of CMV events according to pre-transplant CMV serology, N (%) | |||
| Donor +/Recipient + | 222 (66.1) | 125 (64.8) | 97 (67.8) |
| Donor +/Recipient - | 33 (9.8) | 17 (8.8) | 16 (11.2) |
| Donor -/Recipient + | 13 (3.9) | 7 (3.6) | 6 (4.2) |
| Donor unk/ Recipient + | 55 (16.4) | 35 (18.1) | 20 (14.0) |
| Donor -/Recipient - | 1 (0.3) | 1 (0.6) | 0 (0) |
| Donor unk/ Recipient - | 12 (3.5) | 8 (4.1) | 4 (2.8) |
| Incidence of recurrent CMV events, N (%) | 121 (36.0) | 80 (41.4)(2) | 41 (28.7) |
| Total number of recurrent CMV events | 178 | 110 | 68 |
| Infection | 120 (67.4) | 73 (66.4) | 47 (69.1) |
| Disease | 58 (32.6) | 37 (33.6) | 21 (30.9) |
| Patients with 1 recurrence | 83 (68.6) | 59 (73.8) | 24 (58.5) |
| Patients with 2 recurrences | 24 (19.8) | 13 (16.2) | 11 (26.8) |
| Patients with 3 recurrences | 10 (8.3) | 7 (8.8) | 3 (7.3) |
| Patients with 4 recurrences | 3 (2.5) | 1 (1.2) | 2 (5.0) |
| Patients with 5 recurrences | 1 (0.8) | 0 (0) | 1 (2.4) |
| Total of CMV events | 514 | 303 | 211 |
| Incidence of treated acute rejection before the first CMV event, N (%) | 47 (14.0) | 13 (6.7)(1) | 34 (23.8) |
| Patients with 1 episode | 40 (85.1) | 12 (92.3)(a) | 28 (82.4) |
| Patients with 2 episodes | 7 (14.9) | 1 (7.7) | 6 (17.6)(b) |
| Total of treated acute rejection before the first CMV event, N | 54 | 14 | 40 |
| Incidence of treated acute rejection after CMV event, N (%) | 19 (5.7) | 14 (7.2) | 5 (3.5) |
| Patients with 1 episode | 17 (89.5) | 12 (85.7) | 5 (100) |
| Patients with 2 episodes | 2 (10.5) | 2 (14.3) | 0 (0) |
| Total of treated AR after CMV event | 21 | 16 | 5 |
| Changes in MPS/AZA dosing after CMV events, N (%) | 155 (46) | 101 (52)(3) | 54 (38) |
| Temporary interruption | 63 (41) | 30 (30) | 33 (61) |
| Dose reduction | 69 (44) | 55 (54) | 14 (26) |
| Permanent discontinuation | 18 (12) | 12 (12) | 6 (11) |
| Conversion to other drug | 5 (3) | 4 (4) | 1 (2) |
SD: standard deviation; CMV: cytomegalovirus; unk: unknown; MPS: sodium mycophenolate; AZA: azathioprine.
(1)p = 0.000,
(2)p = 0.016,
(3)p = 0.008 MPS versus AZA.
(a)2 patients presented 1 episode of acute rejection before the first CMV event and 1 episode of acute rejection after CMV event;
(b)1 patient present 2 episodes of acute rejection before the first CMV event and 1 episode of acute rejection after CMV event.
Of 139 patients with first CMV disease 87 (63%) occurred during the period of pp65 antigenemia monitoring every other week. Of them, 19 were D+/R-, 63 were receiving MPS and 5 occurred after treatment for acute cellular rejection. Only 2 patients (D+/R-) presented CMV disease after day 105, the end of pp65 antigenemia monitoring.
The majority of the episodes of CMV diseases were mild, with either leucopenia and/or gastrointestinal manifestations, predominantly diarrhea, with no involvement of lung, liver or pancreas. Prompt recover was observed after treatment with ganciclovir and MPS or AZA dose reduction or interruption. No episodes of invasive CMV disease were confirmed by histologic analysis and there were no deaths directly related to episodes of CMV infection or disease.
Compared to AZA, patients receiving MPS had a higher incidence (33% vs. 52%) and a shorter interval between transplant and the first CMV infection/disease episode, respectively. The incidence of recurrence of CMV infection/disease was higher in patients using MPS (41.4%) compared with AZA (28.7%). The mean duration of treatment with ganciclovir was not different between patients who received MPS or AZA.
The incidence of the first episode of CMV after treatment of acute rejection was higher in patients on AZA (23.8%) compared with MPS (6.7%). Moreover, the incidence of acute rejection after the first episode of CMV infection or disease was higher in treated MPS (7.2%) compared with AZA (3.5%). Changes in the initial immunosuppressive regimen after CMV infection/disease episodes were higher in patients who received MPS (52%) compared with AZA (38%) (Table 2).
Recipients age (OR = 1.03 per year), CMV serological combination D+/R- (OR=5.21), and use of MPS (OR = 1.67) were associated with increased risk of CMV infection/disease. On the other hand, number of HLA mismatches (OR = 0.88 per mismatch) and kidney function at 1 month (OR = 0.98 per ml/min/1.73 m2) were associated with reduced risk of CMV infection/disease (Table 3).
Table 3 Multiple variables analysis to risk of CMV infection or disease
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| Odds Ratio (95% CI) | p | Odds Ratio (95% CI) | p | |
| Recipient age, years | 1.04 (1.03-1.05) | < 0.001 | 1.03(1.02-1.04) | 0.000 |
| Time on dialysis, months | 1.00(1.00-1.01) | 0.005 | 1.00(0.99-1.00) | 0.703 |
| PRA class I | 1.01(1.00-1.01) | 0.051 | ||
| PRA class II | 1.01(0.99-1.02) | 0.067 | ||
| HLA mismatches | 0.83(0.74-0.93) | 0.001 | 0.88(0.77-0.99) | 0.035 |
| CMV serology, Donor (+)/Recipient (-) | 2.88(1.57-5.26) | 0.001 | 5.21(2.55-10.66) | 0.000 |
| Recipient, Caucasian race | 1.01(0.76-1.35) | 0.940 | ||
| Chronic kidney disease due to diabetes mellitus | 1.76(1.19-2.60) | 0.005 | 1.26(0.81-1.94) | 0.304 |
| Donor type | ||||
| Living donor (ref.) | ||||
| Standard criteria deceased donor | 2.00 (1.34-2.99) | 0.001 | ||
| Expanded criteria deceased donor | 5.6(3.53-8.95) | < 0.001 | ||
| Donor age, years | 1.02(1.01-1.03) | < 0.001 | 1.00(0.99-1.01) | 0.867 |
| Delayed graft function, yes | 2.45(1.84-3.23) | < 0.001 | ||
| induction therapy, r-ATG | 2.75(1.83-4.14) | < 0.001 | 1.57(0.99-2.47) | 0.053 |
| immunosuppressive therapy, MPS | 2.18(1.64-2.91) | 0.000 | 1.67(1.22-2.29) | 0.001 |
| Acute rejection, yes | 1.04(0.69-1.56) | 0.849 | ||
| eGFR at 1 month | 0.98(0.97-0.98) | < 0.001 | 0.98(0.98-0.99) | 0.000 |
CI: confidence interval; MPS: sodium mycophenolate; r-ATG: rabbit anti-thymocyte globulin; eGRF: estimated glomerular filtration rate (MDRD4).
CLINICAL OUTCOMES OF EFFICACY AND SAFETY
The group with CMV showed a higher incidence of first treated acute rejection (19 vs. 11%) and first treated biopsy confirmed acute rejection (10% vs. 6%) compared with the group without CMV. These differences were consistently when this analysis was limited to patients receiving either MPS or AZA (Table 4). There were no differences in the incidence of the composite endpoint of efficacy failure, graft loss, death or loss to follow-up. However, a higher percentage of deaths due to infection were observed in the group with CMV (Table 5).
Table 4 Incidence and characteristics of the acute rejection episodes
| Parameters, N (%) | With CMV | Without CMV | ||||
|---|---|---|---|---|---|---|
| Total N = 336 | MPS N = 193 | AZA N = 143 | Total N = 466 | MPS N = 178 | AZA N = 288 | |
| First acute rejection episode, N(%) | 65 (19)a | 25 (13)b | 40 (28)c | 50 (11) | 12 (7) | 38 (13) |
| Biopsy proven acute rejection | 34(10)d | 11(6)e | 23(16) | 27(6) | 7(4) | 20(7) |
| IA | 13(38) | 3(27) | 10(44) | 18(67) | 6(86) | 12(60) |
| IB | 11(32) | 5(45) | 6(26) | 4(15) | 0 | 4(20) |
| IIA | 9(27) | 3(27) | 6(26) | 5(19) | 1(14) | 4(20) |
| IIB | 0 | 0 | 0 | 0 | 0 | 0 |
| III | 1(3) | 0 | 1(4) | 0 | 0 | |
| Borderline changes | 21(6) | 8(4) | 13(9) | 18(4) | 4(2) | 14(5) |
| Clinical acute rejection | 10(3) | 6(3) | 4(3) | 5(1) | 1(1) | 4(1) |
| Time to first acute rejection episode, days (mean ± SD) | 49.0 ± 50.1 | 68.7 ± 78.7 | 42.8 ± 52.1 | 80.5 ± 129.1 | 123.1 ± 170.0 | 52.7 ± 91.8 |
| Total number of treated acute rejection | 75(22) | 30(16) | 45(33) | 55(12) | 13(7) | 42(15) |
| Biopsy proven rejection | 36(48) | 11(6) | 25(18) | 30(55) | 7(4) | 23(8) |
| IA | 13(36) | 3(27) | 10(40) | 21(70) | 6(86) | 15(65) |
| IB | 13(36) | 5(45) | 8(32) | 4(13) | 0 | 4(17) |
| IIA | 9(25) | 3(27) | 6(24) | 5(17) | 1(14) | 4(17) |
| IIB | 0 | 0 | 0 | 0 | 0 | 0 |
| III | 1(3) | 0 | 1(4) | 0 | 0 | 0 |
| Antibody mediated rejection | 0 | 0 | 0 | 1(2) | 1(1) | 0 |
| Borderline changes | 28(37) | 12(6) | 16(11) | 19(35) | 4(2) | 15(5) |
| Clinical acute rejection | 11(15) | 7(4) | 4(3) | 5(9) | 1(1) | 4(1) |
| Treatment | ||||||
| Methylprednisolone | 55(73) | 24(80) | 31(69) | 46(84) | 9(69) | 37(88) |
| Antithymocyte globulin/Methylprednisolone | 20(27) | 6(20) | 14(31)e | 8(14) | 3(23) | 5(12) |
| Immunoglobulin/plasmapheresis | 0 | 0 | 0 | 1(2) | 1(8) | 0 |
| Episodes of acute rejection per patient | ||||||
| Patients with 1 episode | 52(16) | 20(10) | 32(22) | 41(9) | 9(5) | 32(11) |
| Patients with 2 episodes | 10(3) | 5(3) | 5(4) | 5(1) | 2(1) | 3(1) |
| Patients with 3 episodes | 1(0,3) | 0 | 1(1) | 0 | 0 | 0 |
| Patients with 4 episodes | 0 | 0 | 0 | 1(0,2) | 0 | 1(0,3) |
(a)p = 0.001,
(b)p = 0.046,
(c)p = 0.000,
(d)p = 0.023,
(e)p = 0.030 with versus without CMV.
(SD) standard deviation.
Table 5 Efficacy and safety endpoints
| Parameters | With CMV | Without CMV | ||||
|---|---|---|---|---|---|---|
| Total (n = 336) | MPS (n = 193) | AZA (n = 143) | Total (n = 466) | MPS (n = 178) | AZA (n = 288) | |
| Composite endpoint, N (%) | 67 (20) | 31 (16) | 36 (26) | 92 (20) | 38 (21) | 54 (19) |
| BPAR | 34 (10) | 11 (6) | 23 (16) | 27 (6) | 7 (4) | 20 (7) |
| Graft loss | 8 (2)1 | 4 (2) | 4 (3) | 19 (4)3 | 12 (7) | 7 (2) |
| Death | 12 (4)2 | 9 (5) | 3 (2) | 19 (4) | 9 (5) | 10 (3) |
| Lost to follow up | 13 (4) | 7 (4) | 6 (5) | 27 (6) | 10 (6) | 17 (6) |
| Patient survival, (%) | 96.1 | 95.3 | 97.2 | 95.9 | 94.9 | 96.5 |
| Graft survival. (%) | 92.9 | 92.2 | 93.7 | 91.6 | 87.6 | 94.1 |
| Total of graft loss, N (%) | 12 (4) | 6 (3) | 6 (4) | 20 (4) | 13 (7) | 7 (2) |
| Time to graft loss, days (mean ± SD) | 81.83 ± 30.0 | 65.67 ± 23.9 | 98.00 ± 28.0 | 75.90 ± 94.4 | 73.85 ± 97.3 | 79.71 ± 96.2 |
| Cause to graft loss, N (%) | ||||||
| Rejection | 2 (17) | 1 (17) | 1 (17) | 4 (20) | 2 (15) | 2 (29) |
| Technique | 2 (17) | 0 | 1 (17) | 7 (35) | 4 (31) | 3 (42) |
| IF/TA | 1 (8) | 2 (33) | 0 | 8 (40) | 6 (46) | 2 (29) |
| Glomerulonephritis | 1 (8) | 0 | 1 (17) | 0 | 0 (0) | 0 |
| Other | 6 (50) | 3 (50) | 3 (50) | 1 (5) | 1 (8) | 0 |
| Total of deaths. N (%) | 13* (4) | 9 (5) | 4 (3) | 19 (4) | 9 (5) | 10 (4) |
| Time to death, days (mean ± SD) | 164.54 ± 88.70 | 149 ± 70.3 | 199.50 ± 126.3 | 97.16 ± 114.6 | 81.11 ± 93.8 | 111.60 ± 134.0 |
| Cause to death, N (%) | ||||||
| Infection | 11 (84) | 7 (78) | 4 (100) | 11 (58) | 5 (56) | 6 (60) |
| Stroke | 0 | 0 | 0 | 3 (16) | 0 | 3 (30) |
| Cardiovascular | 1 (8) | 1 (11) | 0 | 3 (16) | 2 (22) | 1 (10) |
| Other | 1 (8) | 1 (11) | 0 | 2 (10) | 2 (22) | 0 |
MPS: sodium mycophenolate; AZA: azathioprine; BCAR: Biopsy confirmed acute rejection; SD: standard deviation; IF/TA: interstitial fibrosis and tubular atrophy;
14 out of 12 patients that suffered graft loss had first BCAR;
21 out of 13 patients that died had graft loss first;
31 out of 20 patients that suffered graft loss had BCAR first;
*1 patient suffered graft loss 174 days before death.
RENAL FUNCTION
The incidence of delayed graft function was higher in patients with CMV compared with those without CMV, even considering recipients of kidneys from standard donor (60% vs. 49%) or expanded criteria donors (70% vs. 55%) separately (Table 6). The eGFR at 1 and 12 months were also on average 10 mL/min lower in the group with CMV. This difference was not observed in the subgroup of recipients of kidneys from expanded criteria deceased donors (Table 6). While donor age was associated with increased risk (OR = 1.04 per year), use of induction therapy with r-ATG (OR = 0.57) and eGFR at 1 month (OR = 0.93 per ml/min/1.73 m2) were associated with reduced risk for reduced eGFR at 12 months (Table 7).
Table 6 Renal function
| With CMV | Without CMV | p | |
|---|---|---|---|
| Total | 336 | 466 | |
| DGF, N (%) | 189 (56) | 171 (37) | 0.000 |
| eGFR at 1 month, ml/min, mean ± SD | 41.4 ± 20.7 | 54.3 ± 28.1 | 0.000 |
| eGFR at 12 months, ml/min, mean ± SD | 50.0 ± 19.0 | 61.4 ± 29.4 | 0.000 |
| Living donor | 41 (12) | 127 (27) | |
| eGFR at 1 month, ml/min, mean ± SD | 52.0 ± 19.0 | 62.5 ± 21.8 | 0.006 |
| eGFR at 12 months, ml/min, mean ± SD | 50.7 ± 16.1 | 60.3 ± 18.9 | 0.004 |
| Standard criteria deceased donor | 177 (53) | 274 (59) | |
| DGF, n (%) | 116 (65) | 142 (52) | 0.004 |
| eGFR at 1 month, ml/min, mean ± SD | 43.4 ± 23.1 | 54.0 ± 31.0 | 0.000 |
| eGFR at 12 months, ml/min, mean ± SD | 54.4 ± 20.4 | 66.1 ± 34.5 | 0.000 |
| Expanded criteria deceased donor | 118 (35) | 65 (14) | |
| DGF, n (%) | 87 (74) | 37 (57) | 0.020 |
| eGFR at 1 month, ml/min, mean ± SD | 34.7 ± 14.4 | 38.8 ± 21.0 | 0.129 |
| eGFR at 12 months, ml/min, mean ± SD | 42.6 ± 15.2 | 44.0 ± 17.1 | 0.606 |
DGF: delay graft function; eGFR: estimated glomerular filtration rate by MDRD formula (Modification of Diet in Renal Disease Study equation).
Table 7 Risk factors associated with lower renal function (eGRF < 53 ml/min) 12 months after transplant
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| Odds Ratio (95% CI) | p | Odds Ratio (95% CI) | p | |
| Donor | ||||
| Age, years | 1.06 (1.04-1.07) | < 0.001 | 1.04 (1.02-1.05) | 0.000 |
| Type | ||||
| Living donor (ref.) | ||||
| Standard criteria deceased donor | 1.21 (0.83-1.78) | 0.321 | ||
| Expanded criteria deceased donor | 3.92 (2.42-6.38) | < 0.001 | ||
| Recipient | ||||
| Age, years | 1.03 (1.02-1.04) | < 0.001 | 0.99 (0.98-0.97) | 0.113 |
| Male gender | 0.87 (0.64-1.18) | 0.359 | ||
| Time on dialysis, months | 1.00 (1.00-1.01) | 0.021 | 1.00 (0.99-1.00) | 0.791 |
| PRA class I | 1.00 (0.99-1.01) | 0.581 | ||
| PRA class II | 1.00 (0.99-1.01) | 0.237 | ||
| Transplant | ||||
| HLA mismatch [0- 6] | 0.84 (0.74-0.95) | 0.005 | 0.94 (0.81-1.09) | 0.414 |
| CMV serology, Donor (+)/Recipient (-) | 1.07 (0.57-1.99) | 0.831 | ||
| Delayed graft function | 1.82 (1.35-2.46) | 0.001 | ||
| Induction therapy, r-ATG | 1.59 (1.07-2.36) | 0.023 | 0.57 (0.33-0.98) | 0.041 |
| Immunosuppressive therapy, MPS | 2.16 (1.60-2.93) | < 0.001 | 1.01 (0.67-1.53) | 0.944 |
| Acute rejection, yes | 1.20 (0.78-1.86) | 0.407 | ||
| CMV infection/disease, yes | 1.99 (1.47-2.70) | < 0.001 | 1.14 (0.77-1.68) | 0.518 |
| Renal function at 1 month | 0.93 (0.91-0.94) | < 0.001 | 0.93 (0.92-0.94) | 0.000 |
CI: confidence interval; MPS: sodium mycophenolate.
Tolerability
The incidence of changes in the initial MPS/AZA dosing regimens at 12 months of transplantation was higher in patients with CMV compared with those without CMV (63% vs. 31%). Dose reduction was more frequent in patients receiving MPS while drug discontinuation was more frequent among patients receiving AZA (Table 8).
Table 8 Changes in mycophenolate sodium or azathioprine dosing schedules 12 months after transplantation
| Month 12 | With CMV (n = 299) | Without CMV (n = 400) | ||||
|---|---|---|---|---|---|---|
| Total (n = 299) | MPS (n = 171) | AZA (n = 128) | Total (n = 400) | MPS (n = 146) | AZA (n = 254) | |
| No modification in the initial immunosuppression, n (%) | 112 (37) | 54 (32) | 58 (45) | 277 (69) | 77 (53) | 200 (78) |
| Modification in initial the immunosuppression, n (%) | 187 (63)a | 117 (68)b | 70 (55)c | 123 (31) | 69 (47) | 54 (22) |
| MPS/AZA dose reduction, n (%) | 118 (63) | 81 (69) | 37 (53) | 83 (67) | 56 (81) | 27 (50) |
| MPS/AZA permanent discontinuation, n (%) | 69 (37) | 36 (31) | 33 (47) | 40 (33) | 13 (19) | 27 (50) |
ap = 0.000,
bp = 0.000,
cp = 0.000, with versus without CMV, respectively.
Discussion
This analysis shows the negative influence of CMV infection on kidney transplant outcomes in patients receiving effective immunosuppressive regimens but no CMV pharmacological prophylaxis. Patients who developed CMV infection had a higher incidence of acute rejection episodes, required more changes in the immunosuppressive regimen and showed inferior renal function at 12 months after transplantation.
Considering the immunosuppressive regimens used, including a single dose of 3 mg/kg r-ATG in 82% of patients, and the use of preemptive treatment only in patients deemed at high risk for CMV infection,10 the overall incidence of CMV infection/disease was 42% with almost 60% of them diagnosed by viral replication monitoring. In another study in kidney transplant recipients receiving induction with basiliximab, tacrolimus, mycophenolate and prednisone, the incidence of CMV infection/disease was 38% using a higher cutoff of 10 pp65 CMV positive cells to trigger treatment.11
In a comparable population, but without the use of preemptive therapy, the incidence of CMV disease was 17%. Interestingly, in this study 54% of patients had transient and self-limited CMV viremia12 and there were no cases of invasive CMV disease.
While in this cohort 20% of patients developed CMV disease during pp65 monitoring every other week, only 12% developed CMV disease during weekly pp65 monitoring in our previous study,11 suggesting that the frequency of testing may account, at least in part, for the higher incidence of CMV disease.
On the other hand, this cohort had higher risk for CMV disease, including a high use of r-ATG (82%). Also, in another cohort study we observed that patients developed CMV disease with lower level of viremia compared to those treated for CMV infection, suggesting that other factors such as the individual strength of immune response towards the virus, either cellular or the antibody titer, may be involved.10
The incidence of CMV recurrence was 36% and comparable to other reports.8 However is important to highlight the high number of patients with more than one episode of recurrence, which resulted in a high number of treated episodes, 514 in 330 patients. Patients receiving MPS showed a higher incidence and recurrence of CMV infection or disease, and underwent more changes in the initial immunosuppressive regimen during CMV treatment compared with those receiving AZA, confirming previous observations.
This study confirms that recipient age, D+/R- CMV serostatus, and use of MPS were independent risks factors associated with CMV infection/disease. The use of r-ATG was associated with an increased risk of CMV infection/disease, almost reaching statistical significance. Also, renal function at 1 month was associated with the incidence of CMV infection/disease, a finding observed in another recent cohort study.13 In one interesting cohort study, patients with CMV infection showed more chronic allograft changes early on, even before developing CMV infection.14
This is in agreement with our observation considering the higher prevalence of expanded criteria donors and the higher incidence of DGF in the group of patients who subsequently developed CMV infection/disease. How impaired renal function early increases the risk of CMV infection is unknown, but impaired immunological surveillance and altered pharmacokinetics and pharmacodynamics of the immunosuppressive drugs might be involved. On the other hand, the association between increasing number of HLA mismatches and reduced risk of CMV infection/disease is less clear and deserves further confirmation.
Patients with CMV infection/disease had higher incidence and more severe episodes of acute rejection, and required a higher number of treatments with r-ATG. As expected, no differences in the incidence of graft loss or death were observed between the two groups at the end of first year, although a higher proportion of deaths were due to infections in the group of patients who developed CMV infection/disease. It is recognized that CMV infection also induces a wide range of indirect effects, such as susceptibility to rejection and opportunistic infections.15
At 12 months, mean eGFR was lower in the CMV group compared with patients without CMV, suggesting a possible indirect effect. Nevertheless, among several risk factors associated with renal function at the end of the first year, only recipient age (OR = 1.04 per year), r-ATG use (OR = 0.57) and eGFR at 1 month (OR = 0.93 per ml/min/1.73m2) were independently associated with GFR at 12 months. eGFR at 1 month was used as a surrogate marker for donor type and DGF.
During the first year 46% of patients who developed CMV infection/disease required a temporary or permanent change in the immunosuppressive regimen was necessary, particularly due to hematologic adverse reactions such as leukopenia. At the end of first year, 63% of the patients with CMV had changes in the initial immunosuppressive regimen compared to only 31% in the group without CMV.
Patients who received MPS had a higher proportion of changes in immunosuppressive regimen compared with those receiving AZA. While the most common change in MPS was dose reduction, for AZA, permanent discontinuation occurred in nearly 50% of patients, either in the group with or without CMV. Changes in immunosuppressive regimens have been associated with increased incidence of acute rejection.16 It is possible to speculate that these changes might be associated with subclinical acute rejections influencing renal function at 12 months.
This analysis has several limitations including the single center nature of the study, the demographic characteristics of the population, the immunosuppressive regimens used, and the lack of CMV prophylaxis even for the high risk CMV D+/R- group. On the other hand, the data well represent the national strategies of management of CMV infection, suggesting that more effective strategies to reduce this infection should be investigated and implemented. In the context of our public health system, the use of mTOR inhibitors may be one cost-effective strategy.11
In summary, in a contemporaneous cohort of kidney transplant recipients, the incidence and recurrence rate of CMV infection is high and is associated with higher incidence of acute rejection and need for immunosuppressive drug changes during the first year after transplantation. Besides traditional risk factors, renal function at 1 month was independently associated with CMV infection. Understanding this association is fundamental as we increase the use of kidneys recovered from expanded criteria donors.
